Treatment Decisions in R/R CLL

Author(s):

Yuliya P.L Linhares, MD,Josie Montegaard, MSN, AGPCNP-BC

A medical oncologist provides a comprehensive overview of treatment options for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK inhibitors and CAR T-cell therapy.

EP: 1.Understanding a CLL Diagnosis

EP: 2.Diagnostic Tests in CLL

EP: 3.Goals of Treatment for Patients With CLL

EP: 4.Current First-Line Treatment Options in CLL

EP: 5.Factors That Guide CLL Treatment Decisions

EP: 6.What to Expect from Treatment

EP: 7.Overview of Efficacy and Safety Data for Current CLL Treatment Options

EP: 8.Acalabrutinib-Based Treatment Clinical Trial Updates

EP: 9.Venetoclax-Based Treatment Clinical Trial Updates

EP: 10.Zanubrutinib-Based Treatment Clinical Trial Updates

EP: 11.Ibrutinib-Based Treatment Clinical Trial Updates

EP: 12.Newer Combinations for the Treatment of CLL

EP: 13.What to Know Before Starting Your CLL Treatment

EP: 14.An Overview of Potential Treatment Adverse Effects

Now Viewing

EP: 15.Treatment Decisions in R/R CLL

EP: 16.Shared Decision-Making and Supportive Care in the CLL Treatment Journey

EP: 17.Optimizing Overall Health During CLL Management

EP: 18.Getting the Most From Your CLL Care Team

Video content above is prompted by the following question(s):

For patients with R/R disease, please discuss your approach to treatment.
How do you choose between BTKi in the R/R setting (please provide brief, high-level overview of the data for patients)?
Zanubrutinib vs ibrutinib (ALPINE Extended Follow-up ASH 2023 (Brown NEJM 2023)
Acalabrutinib vs ibruitinib(ELEVATE-RR Byrd J Clin Oncol, 2021) (ELEVATE RR 4-year Follow-up
What is the role forvenetoclax in the R/R Setting?
If a patient fails on one treatment, how do you approach sequencing decisions?

Stay up to date on cancer updates, research and education

Subscribe Now!